Babaodan ameliorates metabolic dysfunction-associated steatotic liver disease with co-modulation of FXR, NF-κB, and SLC22A7 in bile acid metabolism.
- DOI
- 10.1016/j.jep.2026.122201
- Published
- 2027 Jan 10
- Container
- Journal of ethnopharmacology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jep.2026.122201,
title = {Babaodan ameliorates metabolic dysfunction-associated steatotic liver disease with co-modulation of FXR, NF-κB, and SLC22A7 in bile acid metabolism.},
author = {Qiu S and Qiang S and Wang Z and Yang L and Guo S and Zeng J and Cai Y and Lai Z and Xie D and Che L and Zhang A},
year = {2027},
journal = {Journal of ethnopharmacology},
doi = {10.1016/j.jep.2026.122201},
url = {https://doi.org/10.1016/j.jep.2026.122201}
}RIS
TY - JOUR TI - Babaodan ameliorates metabolic dysfunction-associated steatotic liver disease with co-modulation of FXR, NF-κB, and SLC22A7 in bile acid metabolism. AU - Qiu S AU - Qiang S AU - Wang Z AU - Yang L AU - Guo S AU - Zeng J AU - Cai Y AU - Lai Z AU - Xie D AU - Che L AU - Zhang A PY - 2027 JO - Journal of ethnopharmacology DO - 10.1016/j.jep.2026.122201 UR - https://doi.org/10.1016/j.jep.2026.122201 ER -
APA
S, Q., S, Q., Z, W., L, Y., S, G., J, Z., Y, C., Z, L., D, X., L, C., & A, Z. (2027). Babaodan ameliorates metabolic dysfunction-associated steatotic liver disease with co-modulation of FXR, NF-κB, and SLC22A7 in bile acid metabolism.. Journal of ethnopharmacology. https://doi.org/10.1016/j.jep.2026.122201
Source records
- pubmed · retrieved 2026-09-26T07:19:30.463Z
- europe-pmc · retrieved 2026-09-26T07:19:30.479Z